Selexid 200 mg (pivmecillinam)

Product identification and active ingredient

Selexid 200 mg is a branded prescription oral antibiotic whose active ingredient is pivmecillinam hydrochloride — supplied as a 200 mg film‑coated tablet. (medicines.org.uk)

Manufacturing and packaging

Packs of Selexid have been manufactured for European markets by contract manufacturers such as Recipharm Strängnäs AB (Strängnäs, Sweden); regulatory product literature and manufacturing listings identify Recipharm (Sweden) as a common manufacturing site for pivmecillinam/Selexid. Some country‑specific packs have also been produced or repackaged in other EU locations (for example manufacturing/packaging noted in Ireland or repackaging/PL arrangements in the UK), so production is primarily Sweden‑centred but not exclusive to a single site. (imedi.co.uk)

Brand origin and ownership

Selexid was part of the product portfolio historically associated with LEO Pharma (a Danish pharmaceutical company). In 2018–2019 certain rights and product assets (including Selexid) were transferred to Karo Pharma AB, which is now the marketing authorisation holder/ultimate owner for many markets. Documentation from regulatory product pages and Karo Pharma corporate releases reflects this change in ownership and current MAH/marketing responsibilities. (ichgcp.net)

Local licence / distribution notes

In specific markets (for example the UK) there are named product licence holders or repackagers (e.g., Quadrant Pharmaceuticals Ltd and local repackagers listed on patient leaflets), and distributors or pharmacies may receive packs produced in different EU sites. This explains variation in small‑print packaging references across countries. (imedi.co.uk)

Summary

Selexid 200 mg is a prescription pivmecillinam tablet (antibiotic) originally associated with LEO Pharma (Denmark) and currently owned/marketed by Karo Pharma AB (Sweden). Manufacturing is commonly performed in Sweden (Recipharm Strängnäs) though country‑specific packaging and PL holdings mean some production, repackaging or licensing activity can occur in other EU locations. (medicines.org.uk)